The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Inclusion Criteria:

• diagnosis of SIRS, sepsis and/or septic shock,
• older than 18 years, who are being treated with amikacin and/or vancomycin,
• length of use of adsorbent at least 12 hours.

Exclusion Criteria:

• contraindication for hemodiafiltration with adsorbents,
• patients under the age of 18,
• terminal cancer patients.

Adult critically ill patients with a diagnosis of SIRS, sepsis and/or septic shock who are hospitalized in the Department of Medical Intensive Care Medicine